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Introduction—This narrative review considers the key challenges facing healthcare professionals 
and policymakers responsible for providing care to populations in relation to bone health. These 
challenges broadly fall into 4 distinct themes:
1. Case-finding and management of individuals at high risk of fracture
2. Public awareness of osteoporosis and fragility fractures
3. Reimbursement and health system policy
4. Epidemiology of fracture in the developing world
Methods—Findings from cohort studies, randomised controlled trials, systematic reviews and 
meta-analyses, in addition to current clinical guidelines, position papers and national and 
international audits are summarised, with the intention of providing a prioritised approach to 
delivery of optimal bone health for all.
Results—Systematic approaches to case-finding individuals who are at high risk of sustaining 
fragility fractures are described. These include strategies and models of care intended to improve 
case-finding for individuals who have sustained fragility fractures, those undergoing treatment 
with medicines which have an adverse effect on bone health, and people who have diseases 
whereby bone loss and, consequently, fragility fractures are a common comorbidity. Approaches 
to deliver primary fracture prevention in a clinically effective and cost-effective manner are also 
explored.
Public awareness of osteoporosis is low worldwide. If older people are to be more pro-active in the 
management of their bone health, that needs to change. Effective disease awareness campaigns 
have been implemented in some countries, but need to be undertaken in many more. A major need 
exists to improve awareness of the risk that osteoporosis poses to individuals who have initiated 
treatment, with the intention of improving adherence in the long-term. A multisector effort is also 
required to support patients and their clinicians to have meaningful discussions concerning the 
risk-benefit ratio of osteoporosis treatment.
With regard to prioritisation of fragility fracture prevention in national policy, there is much to be 
done. In the developing world, robust epidemiological estimates of fracture incidence are required 
to inform policy development.
Conclusion—As the aging of the Baby Boomer generation is upon us, this review provides a 
comprehensive analysis of how bone health can be improved worldwide for all.
Keywords
Fragility fracture; osteoporosis; case-finding; disease awareness; policy; prioritization; secondary 
prevention; primary prevention
Introduction
In 2016, the first of the Baby Boomer generation entered their eighth decade of life. 
Consequently, the next ten years will bear witness to a significant increase in the number of 
individuals living with osteoporosis and experiencing the morbidity consequent upon 
fragility fractures. Fragility fractures can be defined as fractures which result from a fall 
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from a standing height or less, or that present in the absence of trauma. The most common 
fragility fractures occur at the hip, wrist, spine, humerus or pelvis. As such, it is timely to 
take stock of the key challenges facing healthcare professionals and policymakers 
responsible for providing care for populations in relation to bone health, and to identify 
solutions that will reduce fracture rates and ameliorate their personal and societal burden. 
These challenges broadly fall into 4 distinct themes:
1. Case-finding and management of individuals at high risk of fracture
2. Public awareness of osteoporosis and fragility fractures
3. Reimbursement and health system policy
4. Epidemiology of fracture in the developing world
This narrative review explores each of these themes in terms of current gaps in delivery of 
best clinical practice, levels of public awareness, appropriateness of funding and policy 
arrangements, and characterisation of the current and future burden of disease in the 
developing world. Most importantly, the work of innovators who have successfully 
addressed each challenge will be reviewed. Clinically effective and cost-effective models of 
care have been developed in many countries to case find and manage individuals who are at 
high risk of sustaining fragility fractures. Award winning public awareness campaigns have 
been implemented which empower individuals who are living with osteoporosis to be pro-
active in seeking medical advice to reduce their own fracture risk. A number of governments 
have identified osteoporosis as a national health priority and implemented comprehensive 
quality improvement programs across their national health systems. New epidemiological 
studies from Asia and Latin American have begun to quantify the impact of osteoporosis in 
the developing world. While there is much to be done, there is reason for optimism. All of 
the challenges identified are solvable: now is the time for these solutions to be implemented 
throughout the world.
Case-finding and management of individuals at high risk of fracture
During the last 25 years, a broad range of therapeutic options have become available to 
reduce an individual’ s risk of fragility fracture [1]. These medicines are available as daily, 
weekly or monthly oral tablets, or as daily, three-monthly or six-monthly injections or 
annual infusions, providing patients and physicians with a uniquely flexible array of dosing 
regimens. Getting the right treatment to the right patient at the right time is of paramount 
importance if fracture rates are to be significantly reduced as the world’ s population ages. 
This section of the review focuses on strategies to ensure that individuals who are at high 
risk of sustaining fragility fractures in general, and hip fractures in particular, are reliably 
identified by health systems and treated in accordance with best practice guidance. 
Opportunities to systematise case-finding in four scenarios will be considered:
1. Secondary fracture prevention
2. Primary fracture prevention
3. Osteoporosis induced by medicines
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4. Diseases associated with osteoporosis
For each scenario, evidence relating to fracture risk in the population in question is 
considered. Current levels of case-finding and appropriate osteoporosis management are 
reviewed. Where available, analysis of published work describing models of care to 
implement best practice is presented. Finally, selected examples of clinical guidelines and 
recommendations made therein are highlighted.
Secondary fracture prevention
Secondary fracture prevention is an obvious first step in the development of a systematic 
approach to prevention of all fragility fractures caused by osteoporosis. Since the 1980s, it 
has been known that up to one half of hip fracture patients have already sustained a previous 
fracture [2–5]. Meta-analyses have shown that individuals who have sustained a fracture are 
at approximately double the risk of sustaining subsequent fractures, as compared to their 
fracture-free peers [6, 7]. Accordingly, the notion that fracture begets fracture is well-
established in the literature and well represented in clinical guidelines for osteoporosis in 
many countries [8, 9]. Further, subsequent fractures appear to occur rapidly after an index 
fracture. In 2004, Johnell et al examined the pattern of fracture risk following a prior fracture 
at the spine, shoulder or hip [10]. During 5 years of follow-up, one third of all subsequent 
fractures occurred within the first year after fracture, and less than 9% of all subsequent 
fractures occurred in the fifth year.
The effectiveness of the broad range of currently available osteoporosis treatments has been 
comprehensively reviewed elsewhere [1]. Cochrane Collaboration systematic reviews have 
evaluated alendronate [11], etidronate [12] and risedronate [13] specifically in the secondary 
fracture prevention context for treatment of postmenopausal women, and Cochrane protocols 
have been published for zoledronate [14] and denosumab [15]. The findings of the Cochrane 
reviews for the bisphosphonates which were statistically significant are summarised in table 
1. The methodology used for pooling of results from the individual trials included in the 
Cochrane reviews has been described elsewhere [16]. When the relative risk reduction 
(RRR) for a particular agent was significant (p<0.05), the absolute risk reduction (ARR) and 
number needed to treat (NNT) were calculated. For these calculations, the Cochrane authors 
based the 5-year risk of fracture in the untreated population on the FRACTURE Index (FI) 
[17], and the lifetime and 5-year age-specific risks in the untreated population on the model 
by Doherty et al for predicting osteoporotic fractures in postmenopausal women [18].
Other osteoporosis treatments have been evaluated for secondary fracture prevention in 
randomised controlled trials (RCTs) or sub-analyses of RCTs:
• Zoledronate: The HORIZON Recurrent Fracture Trial (RFT) evaluated 
zoledronate in the treatment of individuals who had sustained a hip fracture [19]. 
Statistically significant reductions were observed for any new clinical fracture 
(RRR 35% [95% CI 16-50%], ARR 5.3%), clinical non-vertebral fracture (RRR 
27% [95% CI 2-45%], ARR 3.1%) and new clinical vertebral fracture (RRR 46% 
[95% CI 8-68%], ARR 2.1%). A non-significant trend towards reduction in hip 
fracture (RRR 30% [95% CI -19-59%], ARR 1.5%) was observed. The safety 
analysis revealed a statistically significant reduction in deaths from any cause for 
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the individuals treated with zoledronate (RRR 28% [95% CI 7-44%], ARR 
3.7%). A sub-group analysis of the HORIZON Pivotal Fracture Trial (PFT) 
observed a comparable effect of zoledronate treatment on the incidence of new 
vertebral and non-vertebral fractures for individuals with and without prevalent 
vertebral fracture at baseline [20].
• Denosumab: A post-hoc analysis of the FREEDOM study evaluated denosumab 
for secondary fracture prevention [21]. A statistically significant reduction in the 
incidence of any subsequent fracture (RRR 39% [95% CI 28-49%], ARR 6.8%) 
was observed, with similar efficacy in those who had prior vertebral fractures 
(RRR 35%, ARR 6.6%) or non-vertebral fractures (RRR 34%, ARR 6.1%) at 
baseline which was highly significant (p<0.0001 for both groups).
• Raloxifene: Among the sub-group of women in the MORE study who had a 
vertebral fracture at baseline, those receiving the licensed 60 mg dose of 
raloxifene sustained significantly fewer new vertebral fractures compared to 
placebo (RRR 30% [95% CI 20-50%], ARR 6%) [22]. However, raloxifene did 
not demonstrate a statistically significant reduction in the incidence of non-
vertebral or hip fractures.
• Teriparatide: In women with postmenopausal osteoporosis and at least one 
vertebral fracture at baseline [23], teriparatide 20 µg per day significantly 
reduced the incidence of new vertebral fractures (RRR 65% [95% CI 45-78%], 
ARR 9.3%) and non-vertebral fragility fractures (RRR 53% [95% CI 12-75%], 
ARR 2.9%). However, the definition of non-vertebral fracture was not directly 
comparable to that used in other studies, and teriparatide did not demonstrate a 
statistically significant reduction in the incidence of hip fractures.
• Strontium ranelate: Strontium ranelate significantly reduced the incidence of new 
vertebral fracture (RRR 41% [95% CI 27-52%], ARR 11.9%) but not non-
vertebral fractures in women with postmenopausal osteoporosis and at least one 
vertebral fracture at baseline [24]. A pooled analysis of the SOTI and TROPOS 
study populations reported a statistically significant reduction in the incidence of 
first vertebral fracture (RRR 46% [95% CI 19-63%], ARR 7.6%) among women 
with a prevalent non-vertebral fracture, who did not have a prevalent vertebral 
fracture [25]. A pre-planned sub-analysis of postmenopausal women with 
osteopenia and a prevalent vertebral fracture, in the combined studies, reported a 
significant reduction in the incidence of new vertebral fractures (RRR 37% [95% 
CI 11-56%], ARR 8.1%) [26].
In light of the diverse array of effective osteoporosis treatments which are available to 
reduce future fracture risk, it is of great concern that a pervasive and persistent secondary 
prevention care gap is evident throughout the world. The International Osteoporosis 
Foundation (IOF) Capture the Fracture® Program website provides an up-to-date 
bibliography of all PubMed cited secondary prevention audits and surveys, undertaken 
internationally, nationally, regionally and locally [27]. Studies from all regions of the world 
feature on the website:
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• Africa: South Africa
• Asia: China, Hong Kong, Japan, Malaysia, Singapore, South Korea, Taiwan, 
Thailand.
• Europe: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, 
The Netherlands, Norway, Sweden, Switzerland, UK
• Latin America: Brazil
• Middle East: Israel, Saudi Arabia
• North America: Canada, USA
• Oceania: Australia, New Zealand
In response to this widely documented care gap, models of care have been developed in 
many countries to ensure that fragility fracture patients receive secondary preventive care – 
which include both osteoporosis management and intervention to prevent falls – in a 
consistent and reliable fashion. The most common models are referred to as Orthogeriatrics 
Services (aka Orthopaedic-Geriatric Co-Care Services or Geriatric Fracture Centers) and 
Fracture Liaison Services (FLS).
The complementary roles of Orthogeriatrics Services and FLS are nicely illustrated in 
consensus guidelines from the UK. In 2007, the British Orthopaedic Association (BOA) and 
the British Geriatrics Society (BGS) published The Care of Patients with Fragility Fracture 
(aka ‘ The Blue Book’ ), with contributions from representatives of the Age Anaesthesia 
Association, Faculty of Public Health, Society for Endocrinology, Royal College of Nursing 
and the UK National Osteoporosis Society [28]. The first section of The Blue Book 
advocated widespread implementation of coordinated, multidisciplinary care for hip fracture 
patients through establishment of Orthogeriatrics Services in hospitals. Such models of care 
are designed to expedite surgery, ensure optimal management of the acute phase through 
adherence to a care plan overseen by senior staff in orthopaedics and geriatrics/internal 
medicine, and deliver secondary fracture prevention through osteoporosis management and 
falls prevention. Implementation of Orthogeriatrics Services has gained momentum globally 
in recent years, supported by development of national hip fracture registries to enable 
benchmarking of the quality of hip fracture care against best practice guidelines [29].
The UK National Health Service (NHS) provides a large scale illustration of the impact that 
Orthogeriatrics Services, supported by a National Hip Fracture Database (NHFD) [30] and 
quality incentives from government [31], can have upon post-hip fracture secondary 
preventive care. The UK NHFD is currently the largest ongoing audit of hip fracture care in 
the world, with more than 454,000 case records entered since it was launched in tandem 
with the Blue Book in 2007 (Personal communication: C. Boulton). The 2015 NHFD 
Annual Report described the care of 64,102 people who presented with a hip fracture in 
2014, representing nearly 95% of all cases in England, Wales and Northern Ireland [32]. 
More than 80% of patients were started on osteoporosis treatment, or were referred for bone 
mineral density (BMD) testing or bone clinic assessment. Further, more than 96% of 
patients were offered a multifactorial risk assessment to identify and address future falls risk, 
and were offered individualised intervention where appropriate.
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The second section of the Blue Book called for widespread implementation of FLS. The 
purpose of an FLS is to ensure that all patients aged 50 years or over who present to health 
services with a fragility fracture undergo fracture risk assessment and receive osteoporosis 
treatment in accordance with national guidelines. The FLS would also refer older patients 
into local falls prevention services. In terms of a ‘ division of labour’ , Orthogeriatrics 
Services typically deliver secondary preventive care for hip fracture patients and FLS deliver 
secondary preventive care for non-hip fragility fracture patients (e.g. wrist, humerus, pelvis 
and those vertebral fractures which come to clinical attention).
During the last 15 years, studies describing the design and performance of FLS have been 
published from many countries [8]. However, variation in FLS service design and reporting 
of processes and outcomes make comparisons between services difficult. In order to 
establish which specific features of an FLS are associated with optimal case-finding and 
implementation of osteoporosis treatment guidelines, Australian investigators undertook a 
systematic review and meta-analysis of the secondary fracture prevention literature [33]. The 
various FLS were classified into four types:
• Type A or 3i FLS models which deliver identification, investigation and initiation 
of interventions.
• Type B or 2i FLS models which deliver identification and investigation, but rely 
on initiation of interventions by the primary care physician (PCP).
• Type C or 1i FLS models which deliver identification and an alert to the PCP that 
further investigations are needed, but rely on the PCP to organise those 
investigations and initiate interventions, where warranted.
• Type D or ‘ Zero i’  models which provide osteoporosis education to the patient, 
but do not alert or educate the PCP.
The proportion of patients undergoing BMD testing and receiving osteoporosis treatment for 
each type of FLS model is shown in table 2. Clearly, Type A (3i) and Type B (2i) FLS 
models result in considerably more fracture patients being investigated and initiated on 
treatment. Whilst practically all osteoporosis treatment guidelines worldwide recommend 
that fragility fracture patients should be assessed for osteoporosis, the proportion that should 
receive osteoporosis treatment remains an ongoing matter of debate. In 2005, the first UK 
National Institute for Health and Care Excellence (NICE) technology appraisal on 
osteoporosis treatments for the secondary prevention of fracture estimated that up to 70% of 
women over 50 years of age with a fragility fracture could benefit from treatment [34]. This 
analysis assumed that all women aged 75 years or over could be indicated for treatment in 
the absence of BMD testing and a smaller proportion of younger women. Given that a 
minority of fracture patients in this age group are likely to suffer early post-fracture 
mortality, 50% to 70% might represent a pragmatic estimate of what would constitute a 
clinically appropriate range for treatment rates among all fragility fracture patients aged 50 
years or over.
A meta-analysis has reported that osteoporosis treatments are associated with reduced 
mortality when taken by individuals who are at high risk of fracture [35]. This finding could 
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be influenced by referral bias: individuals who are perceived to have a low life expectancy 
may be less likely to receive osteoporosis treatments. In 2014, however, in addition to a 
beneficial effect on fracture rates, care delivered by an FLS was shown to reduce mortality 
of fracture patients [36]. The FLS model of care has also been subject to cost-effectiveness 
modelling. An example of this approach is a cohort health-state transition model (a Markov 
model) developed to evaluate the Glasgow FLS in Scotland, UK [37]. The model 
demonstrated that 18 fractures were prevented, including 11 hip fractures, and £21,000 
(€26,250, US$30,000) was saved per 1,000 patients managed by the Glasgow FLS vs ‘ usual 
care’  in the UK.
It should be noted that vertebral fractures make up only a small proportion of FLS case loads 
[38–45], as shown in table 3. This is an important shortcoming which must be addressed 
because vertebral fractures are the most common fragility fracture and are underdiagnosed 
throughout the world [46]. Further, the prevalence of vertebral fractures among individuals 
who sustain hip fractures has been shown to be very high. Studies from Japan and Spain 
reported that 78% and 63% of hip fracture patients had prevalent vertebral fractures, 
respectively [47, 48]. Vertebral fractures were defined by the Japanese and Spanish 
investigators on the basis of the criteria established by The Japanese Society for Bone and 
Mineral Research [49] and Genant [50], respectively. It should be noted that while clinical 
vertebral fractures are a risk factor for hip fracture, asymptomatic grade 1 morphometric 
fractures have no prognostic value [51]. A considerable volume of imaging with plain 
radiography, and X-Rays, CT and MRI scans is undertaken among older people in hospitals 
worldwide every day. Approaches to improve vertebral fracture case-finding from such 
activity has been reviewed elsewhere [52].
Vertebral fracture assessment (VFA) provides a low radiation exposure alternative to 
standard X-ray that could be conducted when patients attend for a DXA scan. This approach 
has been explored in the FLS setting [53, 54]. Amongst patients presenting with non-
vertebral fractures that were assessed by a FLS, the overall prevalence of vertebral deformity 
was of the order of a quarter to a fifth (25% [53] and 20% [54]). VFA identified a substantial 
burden of prevalent vertebral fractures that had not been previously documented. The 
proportion of non-vertebral fracture patients that would be managed differently as a result of 
conducting VFA was relatively small (9% [53] and 3% [54]). This is perhaps not surprising 
given that the patients investigated had a non-vertebral fracture which triggered FLS 
assessment. However, incorporation of VFA into FLS protocols has the potential to reveal 
two sub-groups of non-vertebral fracture patients that may be managed differently as a result 
of ascertainment of vertebral fracture status:
• Patients with ≥ 1 vertebral fracture (grade 2 or higher) and an osteopenic BMD
• Patients with multiple vertebral fractures and profoundly osteoporotic BMD
In both cases, knowledge of the presence of vertebral fractures has the potential to impact 
upon clinical decision making to optimise care for the individual patient’ s circumstances. In 
2007, Siris et al evaluated the combination of ascertaining vertebral fracture status and BMD 
measurement in fracture risk prediction [55]. These investigators concluded:
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“For any given BMD T-score, the risk of an incident vertebral, non-vertebral 
fragility, and any fracture differs by up to twelve times, 2 times, and 7 times, 
respectively, when information regarding spine fracture burden is considered. In the 
absence of knowledge about the prevalent vertebral fracture status, assessments 
based solely on BMD may under- or over-estimate the true risk of a patient 
experiencing an incident fracture”.
Further, when clinicians use the FRAX® tool to calculate an individual’ s fracture risk, the 
notes on risk factors state [56]:
“A special situation pertains to a prior history of vertebral fracture. A fracture 
detected as a radiographic observation alone (a morphometric vertebral fracture) 
counts as a previous fracture. A prior clinical vertebral fracture or a hip fracture is 
an especially strong risk factor. The probability of fracture computed may therefore 
be underestimated. Fracture probability is also underestimated with multiple 
fractures”.
Accordingly, the presence of a vertebral fracture could significantly influence the fracture 
risk calculated by FRAX®. Given that an increasing number of clinical guidelines make 
reference to intervention thresholds based upon a FRAX® score, the decision to treat or not 
may be influenced by knowledge of vertebral fracture status. Another conclusion of the FLS 
VFA work was that VFA should ideally be conducted on all patients that are referred for 
DXA who do not have a clinical fracture history, in order to improve case-finding of 
vertebral fractures [53].
Clinical or Quality Standards for FLS have been developed in Canada [57], New Zealand 
[58] and the UK [59, 60]. IOF has also developed internationally endorsed standards for FLS 
in the form of the Capture the Fracture® Best Practice Framework (BPF) [61–63]. The 
Capture the Fracture® BPF comprises a comprehensive suite of 13 standards:
1. Patient Identification Standard
2. Patient Evaluation Standard
3. Post-fracture Assessment Timing Standard
4. Vertebral Fracture Standard
5. Assessment Guidelines Standard
6. Secondary Causes of Osteoporosis Standard
7. Falls Prevention Services Standard
8. Multifaceted Health and Lifestyle Risk-factor Assessment Standard
9. Medication Initiation Standard
10. Medication Review Standard
11. Communication Strategy Standard
12. Long-term Management Standard
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13. Database Standard
The Capture the Fracture® Program encourages FLS throughout the world to apply for Best 
Practice Recognition which can result in the FLS featuring on the ‘ Map of best practice’  on 
the Capture the Fracture® Program website. In 2015, an analysis of the first 60 FLS to apply 
for Best Practice Recognition was undertaken to confirm that a single framework with set 
criteria was able to benchmark services across healthcare systems worldwide [62]. The FLS 
represented 6 continents and were highly heterogeneous in many aspects, serving 
populations from 20,000 to 15 million individuals, being a mixture of private and publicly 
funded systems, and managing vastly different number of fracture patients at individual 
sites. The assessment process considered performance of the FLS against the standards 
across five domains: (a) patients with hip fractures, (b) patients admitted for other non-hip 
fragility fractures, (c) patients seen primarily in the ambulatory setting with fragility 
fractures, (d) patients with vertebral fragility fractures, and (e) organisational and falls 
services. The domain-level rankings contributed to an overall ranking of Gold, Silver, 
Bronze or Black (insufficient) level of achievements for the FLS, in addition to a score in the 
range 0 to 5. Overall, 27 hospitals scored Gold, 23 Silver and 10 Bronze, with care for the 
hip fracture patients achieving the highest proportion of gold grading for an individual 
domain, while vertebral fracture achieved the lowest. The authors concluded that the BPF 
was fit-for-purpose as a tool to benchmark performance of FLS globally. At the time of 
writing, 174 FLS feature on the map of best practice: 41 ranked Gold, 47 Silver, 20 Bronze 
and 66 still under review or in development.
Government organisations in several countries have supported implementation of systematic 
approaches to fragility fracture care and prevention which prioritise secondary fracture 
prevention, including Australia, Canada, New Zealand, Singapore and UK [8, 64]. The 
overarching strategy originally developed by the Department of Health in England [65] has 
informed policy development in other countries, such as New Zealand [66, 67] as illustrated 
in figure 1.
Primary fracture prevention
Whilst in many populations approximately 1 in 2 women and 1 in 5 men will sustain a 
fragility fracture during their lifetimes after age 50 years [68], at any given point in time, the 
majority of older people lack a fracture history. Strategies to develop clinically effective and 
cost-effective approaches to primary fracture prevention must first establish the size of the 
primary prevention population in a particular jurisdiction. Further, which first fragility 
fracture is to be prevented will significantly influence the cost-effectiveness of such 
strategies, with ‘ hip fracture as first fragility fracture’  being an obvious candidate.
Several studies make quantification of the primary prevention population possible for some 
European countries, which have sought to determine the incidence and prevalence of 
osteoporosis and fragility fractures among postmenopausal women. In 2011, Gauthier et al 
developed a disease model that aimed to estimate the burden of osteoporosis at a national 
level [69]. This model was validated using Swedish data and has since been adapted for 
France [70], Germany [71], Italy [72], and the UK [73]. As illustrated in table 4, the 
individual national models identified the number of women aged 50 years or over in each 
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country based on information from the relevant national statistics organisation. The 
proportion of women with a prior history of at least one fragility fracture varied from 10% in 
France to almost 23% in Sweden. Consequently, the proportion of fracture-free women – the 
primary prevention population – ranged from 77% in Sweden to almost 90% in France.
Studies have not been conducted to determine the proportion of men with a history of at 
least one fragility fracture at any skeletal site in the countries mentioned above. However, a 
compendium of country-specific reports for the European Union countries did provide 
estimates of prior hip and vertebral fracture history for men in 2010 [74]. An associated 
report suggests that the sum of prior hip and prior clinical vertebral fractures represents 
approximately 30% of all prior fragility fractures [75]. The relative proportions of women 
and men in the five countries with a prior history of hip or vertebral fracture in 2010 is 
shown in table 5 (n.b. the populations of women aged 50 years and over differ slightly 
between tables 4 and 5 because of a different data source for the populations being used in 
the compendium of country-specific reports). As is well known, more fractures occur in 
older women compared to older men, resulting in a higher proportion of older women 
having a prior fracture history compared to older men. That being said, approximately one-
third of hip fractures worldwide occur in men, so osteoporosis management of the relatively 
small proportion of men who have a prior history of fracture should not, as is often the case, 
be neglected [76].
While demonstrating cost-effectiveness of a primary fracture prevention strategy is of great 
importance in the cost-constrained circumstances in which many health systems currently 
operate, providing appropriate clinical care to individuals who are at high risk of sustaining 
debilitating first fractures at sites other than the hip should not be ignored. Vertebral 
fractures result in pain, functional disability and decreased quality of life, and are also 
associated with excess mortality [77]. Major non-hip, non-vertebral fractures have been 
demonstrated to be associated with 20% excess mortality during the first 5 years post-
fracture [78].
The secondary fracture prevention care gap has been well documented, as described in the 
previous section of this review. While specific studies have not been undertaken in primary 
fracture prevention, it seems reasonable to assume that a care gap also exists for the high risk 
primary prevention population. A report on osteoporosis in the European Union (EU) 
published in 2013 documented national prescribing levels [75]. These data, in combination 
with an algorithm which calculated the number of patients who were eligible for treatment 
in each of the 27 EU member states at the time, enabled estimation of the potential treatment 
gap for each country in 2010. This approach assumed that all those treated were actually 
eligible for treatment and not at a lower level of risk, so may have underestimated the 
treatment gap among high risk patients. In total in the EU, 10.6 million out of 18.4 million 
women who were eligible received treatment. Among men, 1.7 million men out of the 2.9 
million men who were eligible received treatment.
Strategies to prevent first fractures could function through several ‘ tracks’ . For example, the 
next two sections of this review, relating to osteoporosis induced by medicines and diseases 
associated with osteoporosis, will, in part, serve to deliver primary fracture prevention in a 
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systematic fashion. The advent of absolute fracture risk calculators, such as the FRAX® tool, 
provide a means to stratify fracture risk in the entire older population. The UK National 
Osteoporosis Guideline Group (NOGG) has based its guidance on FRAX®, where an 
intervention threshold for 40 to 90 year olds is set at a risk equivalent to that expected in a 
woman with a prior fracture [79]. Many countries have subsequently adopted the approach 
taken by NOGG [9]. The US National Osteoporosis Foundation (NOF) guidance 
recommends initiation of treatment in the following three scenarios [80]:
• In those with hip or vertebral (clinical or asymptomatic) fractures.
• In those with T-scores ≤−2.5 at the femoral neck, total hip, or lumbar spine by 
dual energy x-ray absorptiometry (DXA).
• In postmenopausal women and men age 50 or older with low bone mass (T-score 
between −1.0 and −2.5, osteopenia) at the femoral neck, total hip, or lumbar 
spine by DXA and a 10-year hip fracture probability ≥3% or a 10-year major 
osteoporosis-related fracture probability ≥20% based on the US version of 
FRAX®.
Just as the FLS model of care has been developed to close the secondary prevention care 
gap, analogous models now need to be developed to deliver primary fracture prevention in a 
systematic fashion. Equipped with knowledge of which medicines induce osteoporosis, what 
other diseases have osteoporosis as a common comorbidity, and online access to absolute 
fracture risk calculators to stratify fracture risk in the population, the necessary case-finding 
tools are now available to develop effective models of care to prevent the first fracture.
Osteoporosis induced by medicines
Many classes of drugs have been shown to adversely affect BMD and/or elevate fracture 
risk. While links have not been proven to be causal in every case, the drug classes shown in 
table 6 have all been associated with fracture outcomes. It is beyond the scope of this review 
to describe in detail the mechanisms of action, epidemiology of BMD loss and/or increase in 
risk of fragility fractures, and utility of interventions to prevent bone loss for each drug class. 
Accordingly, key observations on the impact of each class on BMD and fracture risk are 
indicated in table 6, primarily in accordance with the findings of Panday et al in their 2014 
review on medication-induced osteoporosis [81]. Recent literature reviews specific to each 
drug class are also cited to provide the reader with a source of more detailed current 
information [82–91]. A focus on three commonly used classes – glucocorticoids, androgen 
deprivation therapy and aromatase inhibitors – serves to illustrate the potential benefits of 
strategies to prevent osteoporosis induced by medicines.
Glucocorticoid-induced osteoporosis—Glucocorticoid (GC)-induced osteoporosis is 
the most common cause of secondary osteoporosis [92]. Among adults aged 18 years or over 
it has been estimated that 7.5% have received at least one prescription for an oral GC [93]. 
GCs exert their effects on bone quality and bone mass through a number of direct effects on 
osteoblasts, osteoclasts and osteocytes, in addition to indirect effects mediated through the 
neuroendocrine system, calcium metabolism and muscle [92]. GC-induced fractures occur 
most commonly at sites with significant amounts of cancellous bone, such as the vertebrae 
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and femoral neck. Among chronic GC users, up to 30-50% of patients may sustain fractures, 
depending on the population studied.
Clinical guidelines for the prevention and treatment of GC-induced osteoporosis are 
available in many countries. In 2012, the Joint IOF – European Calcified Tissue Society 
(ECTS) Glucocorticoid-induced Osteoporosis Guidelines Working Group published a 
framework for the development of guidelines for the management of GC-induced 
osteoporosis [94]. This comprehensive framework reviewed the epidemiology of GC-
induced osteoporosis and fracture risk assessment based on 10-year probabilities ascertained 
from FRAX®. A systematic review was performed to assess the efficacy of interventions. 
The Working Group proposed management algorithms which could be tailored to context of 
healthcare delivery in individual countries.
Despite the widespread availability of licensed medications to prevent and treat GC-induced 
osteoporosis, and numerous clinical guidelines to support healthcare professionals to deploy 
these interventions, a major care gap exists. In 2014, Albaum et al published a systematic 
review of studies undertaken between 1999 and 2013 which reported the proportion of 
patients on chronic oral GC therapy who received osteoporosis management [93]. The meta-
analysis included studies from North America, Europe and other regions of the world. The 
majority of studies (>80%) reported that less than 40% of chronic oral GC users received 
BMD testing or osteoporosis therapy. A temporal analysis concluded that there was little 
evidence for improvement over time.
Clinicians from the Geisinger health system in the United States identified the GC-induced 
osteoporosis care gap among their own GC users, despite educational and process changes 
which had been implemented over several years. To overcome this deficiency, a specific 
Glucocorticoid-Induced Osteoporosis Program (GIOP) was developed and implemented 
[95]. The GIOP team included a nurse specialist program leader, physician co-leader, nurse 
specialist care provider, physician consultants and data manager. The stated goals of GIOP 
were:
• Identifying at-risk patients in the Geisinger health system
• Educating patients
• Developing/implementing pathways to improve GC-induced osteoporosis 
diagnosis and treatment
• Monitoring GC-induced osteoporosis outcomes
• Using technology/process flows to ‘make it easy to do the right thing’
Two hundred chronic GS users were seen at baseline, and follow-up visits were scheduled at 
6 and 12 months. Key outcomes of the program at 12 months included:
• Patient retention of knowledge, frequency of exercise, and 25(OH)-vitamin D 
concentrations all significantly improved.
• A significant decrease in GC dose was observed.
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• 91% of patients considered at high fracture risk were taking a bisphosphonate or 
teriparatide, and 96% of patients overall were adherent to their prescribed 
regimen of calcium, vitamin D, and prescription treatment, where indicated.
Geisinger’ s GIOP provides an example of a model of care which can reliably deliver best 
practice in the prevention and treatment of GC-induced osteoporosis.
Androgen Deprivation Therapy-induced osteoporosis—Prostate cancer is the most 
common non-cutaneous malignancy. The current lifetime risk of developing prostate cancer 
(PC) is estimated to be almost 17% (i.e. 1 in 6 men) [96]. Androgen Deprivation Therapy 
(ADT), usually in the form of a gonadotropin-releasing hormone agonist (GnRH), is a 
mainstay of treatment of metastatic, locally advanced or recurrent PC. Currently, 
approximately one-third of PC patients receive ADT [97]. The purpose of ADT is to reduce 
serum testosterone to castrate levels, with the consequent potential to induce osteoporosis 
and increase fracture risk.
Clinical guidelines for the prevention and treatment of ADT-induced osteoporosis are 
available in many countries. In 2013, the IOF Committee of Scientific Advisors (CSA) 
Working Group on Cancer-induced Bone Disease published a position paper on cancer-
associated bone disease [98]. In relation to prostate cancer, the pathophysiology and 
epidemiology of ADT-induced osteoporosis was reviewed. The role of BMD testing and 
fracture risk assessment was considered, in addition to analysis of the evidence-base for the 
prevention of bone loss and fractures with osteoporosis treatments. An algorithm for the 
management of ADT-induced osteoporosis was provided. In 2014, the European Society for 
Medical Oncology (ESMO) published clinical practice guidelines relating to bone health in 
cancer patients, including PC [99]. The guidelines identified three distinct areas of cancer 
management that make consideration of bone health in cancer patients important:
• Bone metastases are common in many solid tumours, including those of the 
prostate.
• Many cancer treatments, including ADT, have effects on reproductive hormones 
which can adversely affect the process of normal bone remodelling.
• On account of the bone marrow micro-environment being intimately involved in 
metastatic processes, bone-targeted treatments can reduce metastasis of cancer to 
bone and so, potentially, improve survival.
The ESMO guidelines provide a management algorithm and practical recommendations on 
optimising bone health for cancer patients.
While the osteoporosis care gap for ADT-induced osteoporosis has not been documented as 
comprehensively as is the case for secondary fracture prevention and GC-induced 
osteoporosis, local studies from several countries suggest that a gap exists:
• Canada: In 2012, a cross-sectional survey-based study was conducted involving 
practicing urologists and genitourinary radiation oncologists across Canada 
[100]. The majority of respondents correctly identified the guideline-concordant 
frequency of repeat DXA scans (76.3%), vitamin D (70.3%), and calcium 
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(53.2%) intake and that bisphosphonates/denosumab should always be 
considered for patients with a history of one low-trauma fracture (57.6 %). 
However, in practice, only one third (32.5%) reported routinely measuring BMD 
prior to starting ADT and routinely measuring BMD 1-2 years following the 
initiation of ADT (36.6 %). Less than 5% of respondents routinely used a 
validated fracture risk assessment tool.
• India: In 2011, telephone interviews were undertaken with 108 members of the 
Urological Society of India. Less than one fifth (19.8%) of urologists routinely 
measured BMD before starting ADT. Only half of respondents stated that they 
advised their patients that osteoporosis and adverse skeletal events could be a 
side effect of ADT. While a majority of urologists (59.6%) frequently used 
zoledronic acid in their clinical practice, approximately half of these users 
prescribed the bisphosphonate to men without knowledge of their BMD status. 
Very limited access to BMD testing in India is likely to contribute to this 
practice, as reported in the IOF Asia-Pacific Regional Audit published in 2013 
[101].
• United States: Men diagnosed with PC between 2005 and 2007 in the Texas 
Cancer Registry/Medicare linked database (n=2,290) were analysed to determine 
what proportion underwent BMD testing and/or received osteoporosis treatment 
[102]. Less than one tenth (8.6%) underwent DXA within 1 year before and 6 
months after initiation of ADT. Among the approximately 50% of study subjects 
who were enrolled in the Medicare part D scheme (n=1,060), 5.6% received bone 
sparing drugs when started on ADT, and 12.6% received bone sparing drugs or 
underwent DXA.
The Kaiser Permanente Healthy Bones Program has specifically focused on delivery of 
appropriate osteoporosis assessment to men diagnosed by PC between 2003 and 2007 in the 
Kaiser Permanente Southern California health system [97]. The investigators created two 
study cohorts:
• Healthy Bones Program (HBP) Group: Any patient with PC who underwent 
BMD measurement at most 3 months before their first administration of ADT.
• Non-HBP Group: All other PC patients.
Men managed by the HBP group with BMD T-scores ≥ -2.5 received lifestyle advice 
relating to smoking cessation, exercise and adequate intake of calcium (1,200 mg/day) and 
vitamin D (400-800 IU/day). Men with T-scores < -2.5 were also treated with a 
bisphosphonate and followed up by an endocrinologist. The incidence rate of hip fractures 
per 1,000 person-years was 5.1% (95% CI, 3.0-8.0) in the HBP Group as compared to 
18.1% (95% CI, 10.5-29.0) in the non-HBP Group.
Kaiser Permanente’ s HBP provides an example of a model of care which can reliably deliver 
best practice in the prevention and treatment of ADT-induced osteoporosis.
Aromatase inhibitor-induced osteoporosis—Breast cancer (BC) is the most common 
neoplasm in women, and the leading cause of cancer-related mortality in women [103]. One 
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in eight women will develop BC during their lifetime, and it accounts for almost a quarter 
(23%) of total cancer cases and 14% of all cancer-related deaths. Aromatase inhibitors (AI) 
are currently considered to be the gold standard adjuvant treatment for postmenopausal 
women with hormone receptor-positive BC. The aromatase enzyme converts androgens into 
estrogens providing the main source of endogenous estrogens after the menopause. Thus, 
bone loss and increased fracture risk is an expected side effect of AI therapy.
Clinical guidelines for the prevention and treatment of AI-induced osteoporosis are available 
in many countries. In 2012, the European Society for Clinical and Economical Aspects of 
Osteoporosis (ESCEO) published guidance on prevention of bone loss and fractures in 
postmenopausal women treated with AIs [85]. Key recommendations included:
• All women starting AI therapy should be assessed for their baseline risk of 
sustaining a fragility fracture, using DXA examination, biochemical assessment 
and evaluation of all clinical risk factors with the FRAX® tool.
• General advice on appropriate levels of physical exercise and vitamin D and 
calcium intake should be given.
• Antiresorptive treatment should be offered to the following groups:
– Pre-menopausal women with ovarian suppression undergoing 
tamoxifen or AI therapy with T-score < -1.0 or presence of ≥ 1 
vertebral fracture or history of fragility fracture (any site, irrespective 
of BMD).
– Post-menopausal women with history of personal fragility fracture (any 
site) or age ≥ 75 years old (irrespective of BMD).
– Post-menopausal women with T-score < -2.5 or < -1.5 + ≥ 1 clinical 
risk factor or T-score < -1.0 + ≥ 2 clinical risk factors or FRAX® 10-
year risk of hip fracture ≥3%.
While the osteoporosis care gap for AI-induced osteoporosis has not been documented as 
comprehensively as is the case for secondary fracture prevention and GC-induced 
osteoporosis, studies from the UK [104] and United States [105] have again identified a care 
gap. The US study reported that less than half (44%) of women underwent BMD testing 
within 14 months of continuous AI use for at least 9 months [105]. Furthermore, 75% and 
66% of women failed to have BMD tests done during the second and third annual time 
periods after continuous AI use for almost 2 and 3 years, respectively.
Quality improvement initiatives from Italy [106] and UK [104] provide examples of efforts 
to manage bone health of women treated with AI therapy in a systematic fashion. 
Investigators from London, UK used a text recognition system installed on the computers of 
secretaries in the oncology department to automate referral of women age 50 to 80 years 
who were undergoing treatment for BC to an Osteoporosis Nurse Specialist (ONS) [104]. In 
addition, text was automatically inserted into letters from the oncology department to 
patients’  PCP, advising them that their patient would receive an osteoporosis assessment and 
management, where warranted. The proportion of BC patients referred for osteoporosis 
assessment increased 10-fold upon implementation of this system.
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Diseases associated with osteoporosis
Many diseases predispose an individual to developing osteoporosis and/or sustaining 
fragility fractures. These comprise a broad array of disorders including autoimmune, 
digestive and gastrointestinal, endocrine and hormonal, hematological, neurological, mental 
illness, cancer and AIDS/HIV. An overview of associations between several common 
diseases [107–112] and bone loss and/or fracture risk [113–120], and current evidence for 
the existence of an osteoporosis care gap [121–125] for individuals with these diseases is 
provided in table 7. For some of the diseases, the frequent presence of osteoporosis as a 
comorbidity has prompted development of disease-specific clinical guidelines intended to 
reduce fracture risk [126–128]. Where guidelines have been developed, efforts should be 
made throughout the world to implement their recommendations to improve the bone health 
of these individuals as a standard component of management of the particular disease. With 
regard to diabetes, in light of the enormous number of individuals already affected, 
evidence-based guidelines for the management of osteoporosis in type 2 diabetes must be 
drafted and implemented as soon as possible. Similarly, evidence-based guidelines for the 
management of osteoporosis - and falls risk - in dementia must be drafted and implemented 
globally.
Public awareness of osteoporosis and fragility fractures
Throughout the world, public awareness of osteoporosis and the fragility fractures it causes, 
is low. If the projected dramatic increase in the number of individuals sustaining fragility 
fractures in the first half of this century is to be attenuated, awareness must be increased. 
This section of the review will consider three key aspects of raising awareness and 
eliminating current confusion among lay people:
• The importance of staying on treatment
• Public awareness of osteoporosis and fracture risk
• Public awareness of benefits versus risks of osteoporosis treatment
A determined global effort is required, involving healthcare professionals and their 
organisations, patient societies and policymakers, to provide the public with clear, consistent 
and compelling messages regarding bone health. Focusing on these three issues provides a 
framework to achieve that objective.
Adherence to treatment
There are two measures of adherence to treatment which are commonly used in studies; 
maximal achievement of these often requires contribution from prescriber as well as the 
patient:
• Persistence: Defined as either the time to treatment discontinuation or as the 
proportion of patients that at a certain time point still fill prescriptions without a 
gap in refills longer than an allowed period of time (e.g., 30, 60 or 90 days).
• Compliance: Defined as the ability of a patient to adhere to the dosing, timing 
and conditions described by the prescriber or in accordance with the medicine’ s 
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patient information leaflet. One indirect measure of compliance is the medication 
possession ratio (MPR). MPR is usually defined as the number of days of 
medication available to the patient, divided by the number of days of 
observation.
Osteoporosis is a long-term condition which, therefore, requires a long-term management 
plan. Frequently, individuals at high risk of sustaining fragility fractures who have been 
initiated on osteoporosis treatment cease to take that treatment within the first year [129]. 
This problem should come as no surprise to our field as this phenomenon has been widely 
reported for other classes of medicines for treatment of chronic diseases, such as anti-
hypertensives and statins. That being said, osteoporosis is somewhat unique in medicine in 
terms of the flexibility of dosing options that are available to patients, including daily, 
weekly or monthly tablets, and daily, quarterly, six-monthly or annual injections or 
infusions. Accordingly, a first important step in raising awareness of osteoporosis is to 
ensure that individuals who have been initiated on drug therapy understand why their 
physician has decided that treatment is warranted.
In 2013, the Medication Adherence and Persistence Special Interest Group of the 
International Society For Pharmacoeconomics and Outcomes Research (ISPOR) undertook a 
systematic literature review of interventions to improve osteoporosis medication adherence 
[130]. Key findings included:
• Patients were most persistent with medications which had the least frequent 
dosing regimens.
• Electronic prescriptions in combination with verbal counselling were associated 
with a 2.6-fold improvement in short-term compliance compared to verbal 
counselling alone.
• With regard to patient education based interventions, the largest and least biased 
studies reviewed showed only marginal improvement in adherence.
An emerging body of evidence suggests that osteoporosis treatment initiated by a FLS for 
fragility fracture patients is more likely to be adhered to than regimens for patients managed 
in other settings. In 2011, the FLS at the University Hospital of St. Etienne, France evaluated 
adherence among 155 fracture patients who were initially prescribed a specific osteoporosis 
treatment by the FLS [131]. Among the 90% of patients (n=140) who actually used the 
prescription to begin treatment, 80% were still taking treatment at 12 months. In terms of 
longer term persistence, after 27.4 months (±11.7 months) of follow-up, 68% of patients 
were persistent with their treatment. Among the persistent patients, 87% reported that they 
continued to comply with both the treatment dosing and administration conditions. In 2014, 
similar findings were reported by the FLS at Amiens University Hospital, France [132]. The 
proportion of patients initially treated by the FLS who continued to take treatment at 12 
months and 18 months was 74% and 67%, respectively. A report from the FLS at Concord 
Repatriation General Hospital, Sydney, Australia compared adherence among patients 
initiated on treatment by the FLS who were subsequently followed up by either the FLS or 
local PCPs [133]. Persistence at 24 months was similar in both groups leading the 
investigators to conclude that the main function of an FLS is to initiate a management plan 
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for osteoporosis after fractures occur. If effective communication between the FLS and local 
PCPs is established, PCPs are well-placed and willing to manage osteoporosis care in the 
longer term.
Awareness of osteoporosis and fracture risk
In recent years, numerous studies have been conducted to characterise public awareness and 
understanding of osteoporosis, fracture risk and the link between them. In 2008, 
investigators from Kaiser Permanente Northwest, USA sought to evaluate stakeholder 
perspectives on post-fracture osteoporosis care delivered by an outreach program which 
targeted patients and PCPs [134]. Qualitative evaluation was undertaken by semi-structured, 
in-depth individual interviews with women aged 67 years or older who had sustained a 
clinical fracture (n=10), PCPs (n=9), quality and other healthcare managers (n=20), and 
orthopaedic clinicians and staff (N=28). As compared to other common conditions, PCPs 
noted, and patients demonstrated, a lack of understanding of osteoporosis and its 
management, which included:
• Fatalism: Osteoporosis being confused with osteoarthritis, so promoting the 
notion that osteoporosis is an inevitable but benign consequence of aging.
• Media influence: PCPs noted that patients would often seek BMD testing in 
response to suggestions to do so in the popular press.
• Long-term treatment: Patients expressed concern regarding the duration of 
treatment with specific osteoporosis therapies, and uncertainty regarding the 
consequence of stopping treatment.
In 2013, investigators from Toronto, Canada evaluated fragility fracture patients’  
understanding of the link between osteoporosis and fractures [135]. The participants were 
drawn from a database created by the provincial post-fracture screening programme, a 
component of the Ontario Osteoporosis Strategy. The main outcome for the study was 
fracture patients’  response to the question ‘ Do you think your broken bone could have been 
caused by having osteoporosis (thin or brittle bones)?’  The range of responses that were not 
in the affirmative were collapsed into one category ‘ did not make the link’ . At baseline, 93% 
(1,615/1,735) of fracture patients did not believe that their fracture could have been caused 
by osteoporosis. At follow-up, only 8.2% changed their perception. In adjusted analyses, 
several baseline characteristics were shown to be predictive of individuals who would be 
more likely to make the link. These included individuals who had sustained a previous 
fracture (odds ratio [OR] 1.7, 95% CI, 1.2-2.6), perception of osteoporosis pharmacotherapy 
benefits (OR 1.2, 95% CI, 1.0-1.5), diagnosis of rheumatoid arthritis (OR 2.6, 95% CI, 
1.4-4.9) and perception of bones as ‘ thin’  (OR 8.2, 95% CI, 5.1-13.1).
The international GLOW study has compared self-perception of fracture risk with actual risk 
among more than 60,000 postmenopausal women in 10 countries in Europe, North America, 
and Australia [136]. Key findings included:
• Among women reporting a diagnosis of osteopenia or osteoporosis, only 25% 
and 43%, respectively, thought their fracture risk was increased.
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• Among women whose actual fracture risk was increased based on the presence 
of any one of seven risk factors for fracture, the proportion who recognized their 
increased risk ranged from 19% for smokers to 39% for current users of 
glucocorticoid medication.
• Only 33% of those with at least 2 risk factors perceived themselves as being at 
higher risk.
These studies illustrate that a major awareness gap exists in terms of what osteoporosis 
actually is, and how osteoporosis underpins fracture risk. A number of Disease Awareness 
Campaigns (DAC) have been developed to provide the public with clear, evidence-based 
messages relating to osteoporosis and reducing fracture risk. The 2Million2Many Campaign 
from the National Bone Health Alliance (NBHA) in the United States provides an innovative 
example of implementing this approach [137]. The key messages for 2Million2Many are 
very simple and compelling:
• Every year, there are 2 million bone breaks that are no accident (in the USA).
• They are the signs of osteoporosis in people as young as 50.
• But only 2 out of 10 get a simple follow-up assessment.
• Together we can break osteoporosis before it breaks us. But we must speak up. 
Remember:
- Break a bone, request a test.
The impact of the 2Million2Many campaign cannot be assessed in isolation, because 
pursuant to the launch of this campaign in 2012, NBHA and NOF launched a major FLS 
implementation initiative in 2013 and a Qualified Clinical Data Registry focused on 
outcomes in osteoporosis and post-fracture care in 2014 [137]. In 2015, the National 
Committee on Quality Assurance (NCQA) published The State of Health Care Quality 2015 
which reported on post-fracture osteoporosis care for women for the period 2007 to 2014 
[138]. The concurrence of the NBHA/NOF initiatives and an improvement in post-fracture 
care in the United States is illustrated in figure 2.
In light of the widely documented secondary fracture prevention care gap described 
previously in this review, the initial focus of DACs should be to drive awareness throughout 
the population of the world that fracture begets fracture, and that appropriate assessment and 
intervention, where warranted, can reduce the incidence of subsequent fractures.
Awareness of benefits and risks of osteoporosis treatments
During the last decade, treatment of osteoporosis has become embroiled in considerable 
controversy in the media on account of reports of rare side effects in the clinical literature. 
Mass media coverage of studies describing the incidence of osteonecrosis of the jaw (ONJ), 
atrial fibrillation (AF) and atypical femur fractures (AFF) have caused alarm and confusion 
among patients and PCPs. The importance of vigilant adverse event monitoring cannot be 
understated. However, healthcare professionals and their patients must not lose sight of the 
fact that the risk-benefit analysis in individuals who are at high risk of sustaining fragility 
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fractures strongly favours treatment [139]. The current evidence-base regarding the 
incidence of ONJ, AF and AFF can be summarised as follows:
• ONJ: In 2015, an International Task Force estimated the incidence of ONJ in the 
osteoporosis population to be 0.001% to 0.01%, which was marginally higher 
than the incidence observed in the general population of <0.001% [140].
• AF: In 2015, a systematic review and meta-analysis determined the effects of 
bisphosphonates on AF, total adverse cardiovascular (CV) events, myocardial 
infarction (MI), stroke, and CV death in adults with or at risk for low bone mass 
[141]. While the risk of AF was modestly but not significantly elevated for 
zoledronic acid exposure (6 trials; OR 1.24, 95% CI, 0.96–1.61), it was not for 
oral bisphosphonates (26 trials; OR 1.02, 95% CI, 0.83–1.24).
• AFF: In 2012, investigators from Kaiser Permanente in the United States 
analysed a large population of bisphosphonate users to explore the relationship 
between duration of therapy and risk of AFF [142]. Age-adjusted incidence rates 
for an AFF were 1.78 per 100,000 person years (95% CI, 1.5-2.0) with exposure 
from 0.1 to 1.9 years, which increased to 113.1 per 100,000 person years (95% 
CI, 69.3-156.8) with exposure from 8 to 9.9 years. The authors concluded that 
the incidence of AFF increases with longer duration of bisphosphonate use, but 
this risk should be counterbalanced with the proven benefits in terms of fracture 
reduction.
In 2016, an analysis of hip fracture patients insured by United HealthCare in the United 
States observed that post-hip fracture bisphosphonate treatment had declined from 15% in 
2004 to 3% in the last quarter of 2013 [143]. During this period, the US Food and Drug 
Administration (FDA) issued three drug safety announcements relating to bisphosphonates 
and ONJ (2005), AF (2007) and AFF (2010). For the period 2003-2007, a 4% increase in 
bisphosphonate prescribing for hip fracture patients was observed every quarter (OR 1.04, 
95% CI, 1.02-1.07). Pursuant to the 2007 FDA announcement on AF, this trend was 
reversed, with a 4% decrease in bisphosphonate use every quarter (OR 0.94, 95% CI 
0.93-0.99). This sequence of events is clearly at odds with global efforts, including 
multisector collaboration in the United States through NBHA (a public-private partnership 
with five government liaisons from FDA, the Centers for Disease Control and Prevention 
[CDC], Centers for Medicare and Medicaid Services [CMS], National Aeronautics and 
Space Administration [NASA] and National Institutes of Health [NIH]) [137], to prevent 
individuals who have sustained serious fragility fractures from sustaining further and 
potentially life-threatening fractures. This experience underscores the need for healthcare 
professionals, their professional organisations and regulatory agencies to deliver balanced, 
tailored and meaningful information to patients regarding risk-benefit ratios.
Reimbursement and health system policy
In contrast with other comparable common non-communicable chronic diseases, 
osteoporosis has often not attracted a commensurate level of attention from health providers 
and governments. This section of the review will summarise findings relating to 
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reimbursement and health system policy from regional audits conducted during this decade 
by IOF. An overview of the current situation in North America is also provided.
Access and reimbursement for osteoporosis assessment and treatment
Asia-Pacific—In 2013, IOF published the Asia-Pacific Regional Audit which provided an 
overview of the epidemiology, costs and burden of osteoporosis for 16 jurisdictions: 
Australia, China, Chinese Taipei, Hong Kong, India, Indonesia, Japan, Malaysia, New 
Zealand, Pakistan, Philippines, Republic of Korea, Singapore, Sri Lanka, Thailand and 
Vietnam [101]. This audit also provided information on access and reimbursement for 
diagnosis and treatment of osteoporosis. While Australia, Hong Kong, Japan, New Zealand, 
Republic of Korea and Singapore had 12-24 DXA machines per million of population, 
China, India, Indonesia, Pakistan, Philippines, Sri Lanka and Vietnam were severely under-
resourced with less than 1 DXA machine per million of population. Further, BMD testing 
was not fully reimbursed in many countries, which served as a barrier to accessing 
treatment. Reimbursement of osteoporosis treatment varied greatly across the region, 
ranging from zero to 100% reimbursement for the most commonly prescribed medications.
Eastern Europe and Central Asia—In 2010, IOF published the Eastern European and 
Central Asian Regional Audit which provided an overview of the epidemiology, costs and 
burden of osteoporosis for 21 countries: Armenia, Azerbaijan, Republic of Belarus, 
Bulgaria, Czech Republic, Estonia, Georgia, Hungary, Republic of Kazakhstan, Kyrgyz 
Republic, Latvia, Lithuania, Republic of Moldova, Poland, Romania, Russian Federation, 
Slovakia, Slovenia, Republic of Tajikistan, Ukraine and Republic of Uzbekistan [144]. The 
number of DXA machines per million of population ranged from 20 in Slovenia to less than 
1 in many Central Asian countries. In most countries, BMD testing was only accessible in 
the main cities. However, more than 40% of the population resides in a rural area in about 
one third of the countries. Reimbursement of osteoporosis treatment varied considerably 
between countries. In the Russian Federation, salmon calcitonin was the only treatment 
available.
European Union—In 2013, IOF in collaboration with the European Federation of 
Pharmaceutical Industry Associations (EFPIA) undertook a comprehensive osteoporosis and 
fragility fracture audit of the 27 EU member states at the time [74, 75, 145]. The audit used a 
previous estimate that European countries required 11 DXA machines per million of 
population to provide adequate osteoporosis care [146]. Austria, Belgium, Cyprus, 
Denmark, Finland, France, Germany, Greece, Italy, Portugal and Slovenia exceeded this 
threshold, while 9 countries were considered to have very inadequate provision (Bulgaria, 
Czech Republic, Hungary, Latvia, Lithuania, Luxembourg, Poland, Romania and the UK). 
Eighteen countries offered unconditional reimbursement for DXA scanning. While most 
treatments were reimbursed in most countries, full reimbursement without income 
conditions was provided in only 7 member states (Austria, Germany, Italy, The Netherlands, 
Slovenia, Sweden and UK). In the remaining countries, the level of reimbursement varied 
from zero in Malta up to 100% for selected treatments in Luxembourg and Spain.
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Latin America—In 2012, IOF published the Latin America Regional Audit which 
provided an overview of the epidemiology, costs and burden of osteoporosis for 14 
countries: Argentina, Bolivia, Brazil, Chile, Columbia, Costa Rica, Cuba, Guatemala, 
Mexico, Nicaragua, Panama, Peru, Uruguay and Venezuela [147]. Brazil and Chile had 10 
DXA machines per million of population, while other countries ranged from 0.9 to 6.7 per 
million of population. Access to BMD testing was often limited to urban areas throughout 
the region. Bisphosphonates were widely available throughout the region with considerable 
variability in reimbursement policy. Other osteoporosis therapies were also available, but 
access was often restricted.
Middle East and Africa—In 2011, IOF published the Middle East and Africa Regional 
Audit which provided an overview of the epidemiology, costs and burden of osteoporosis for 
17 countries: Bahrain, Egypt, Kuwait, Iran, Iraq, Jordan, Kenya, Lebanon, Morocco, 
Palestine, Qatar, Saudi Arabia, South Africa, Syria, Tunisia, Turkey, United Arab Emirates 
[148]. The number of DXA machines per million of population ranged from 27 in Lebanon 
to zero in Kenya. In most countries, BMD testing was only accessible in urban areas. 
Reimbursement for DXA scanning and osteoporosis treatment varied widely throughout the 
region.
North America—IOF has not conducted an audit in North America. Accordingly, the 
authors of this review sought a current summary of access and reimbursement for 
osteoporosis assessment and treatment from Osteoporosis Canada (Personal communication: 
D. Theriault) and National Osteoporosis Foundation in the United States (Personal 
communication: D. Lee).
In Canada there is no single national healthcare system. Healthcare falls under the 
independent jurisdiction of each of the 10 provinces and 3 territories. There is 
reimbursement for many of the oral bisphosphonates in all Canadian provinces for seniors 
who are indicated for such treatment. However, coverage for other osteoporosis medications 
such as denosumab and zoledronic acid is quite variable depending on the province/territory.
In the United States, reimbursement for screening, treatment and other bone health 
interventions varies greatly depending on each patient’ s health plan. To address these gaps, 
NBHA will convene a bone health ‘ payer summit’  in 2017 comprising the major payers to 
solicit their feedback on the scientific and clinical evidence needed to reconsider these 
coverage and reimbursement decisions. This feedback will be used to inform the 
development of an evidence report that will provide evidence of the cost-effectiveness of 
these interventions to reduce future fracture risk.
Fragility fracture prevention in national policy
As for the previous section of this review, the IOF regional audits provide comprehensive 
information on the level of priority afforded to fragility fracture prevention by governments 
in the various regions of the world, which is summarised in table 8 [67, 74, 75, 101, 144, 
145, 147, 148]. With regard to the current situation in North America, Osteoporosis Canada 
(Personal communication: D. Theriault) and the National Osteoporosis Foundation in the 
United States (Personal communication: D. Lee) have provided summaries.
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In Canada, provincial healthcare administrators are becoming increasingly aware of the 
compelling benefits of FLS in reducing the fracture burden and the associated healthcare 
costs. OC has launched a FLS Registry to showcase Canadian FLS meeting all 8 of the 
Essential Elements for Fracture Liaison Services [149].
In the United States, health care reform is evolving from fee for service to supporting 
improved quality, prevention and care coordination with financial incentives (or penalties) to 
encourage healthcare professionals and health systems to report on and improve patient 
outcomes. There are a number of quality measures focused on osteoporosis and post-fracture 
care but performance around these measures remains low compared to other major chronic 
diseases. Further, a major drop in reimbursement for DXA scans performed in the office 
setting has led to a drop in the number of providers and more than 1 million less DXA scans 
performed per annum.
Fracture epidemiology in the developing world
It is well recognised in the literature that in the coming decades the burden of fragility 
fractures will increasingly be borne by older people living in the developing world [150]. 
The IOF regional audits noted a dearth of data pertaining to fracture epidemiology in many 
developing countries [101, 144, 147, 148]. Arguably, the most obvious example of this 
challenge is India, which is poised to become the world’ s most populous country in the next 
few decades. The 2013 IOF Asia-Pacific audit identified the pressing need for multicentre, 
large-scale hip fracture incidence studies to be conducted [101]. In due course, efforts by the 
Indian Society for Bone and Mineral Research (ISBMR) will provide robust fracture 
epidemiology to inform development of policy on fracture prevention in India. Similar 
initiatives are needed in Malaysia, Pakistan, Sri Lanka, Thailand and Vietnam.
In the course of the development of new FRAX® models, epidemiological estimates of the 
incidence of fractures have become available for major countries such as Brazil [151] and 
the Russian Federation [152]:
• Brazil: In 2015, there were estimated to be 80,640 hip fractures in Brazil, of 
which 23,422 were in men and 57,218 in women. In 2040, the number of hip 
fractures is expected to rise to 55,844 in men and 141,925 in women, a rise of 
238 and 248 %, respectively.
• Russian Federation: Extrapolation of robust fracture information collected in 
Yaroslavl and Pervouralsk to the entire population of the Russian Federation 
suggests that 112,000 hip fractures occurred in 2010. This was expected to rise to 
159,000 in 2035. The estimated number of major osteoporotic fractures was 
expected to rise from 590,000 to 730,000 over the same time interval. Further 
large scale, multi-centre epidemiological studies should be conducted in Russia 
to confirm these estimates.
Provision of robust epidemiological estimates of fracture incidence throughout Asia-Pacific, 
Central Asia, Latin America, the Middle East and Africa will be a critical step towards 
supporting development of fracture prevention policies for these rapidly aging populations.
Harvey et al. Page 24
Osteoporos Int. Author manuscript; available in PMC 2017 November 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Summary and Call to Action
The first of the Baby Boomer generation began to retire in 2011. At that time, an editorial in 
this journal noted that 450 million people would celebrate their 65th birthday during the 
subsequent two decades [150]. Today, in 2016, a good number of them already have done so. 
In the absence of implementation of an evidence-based, multidisciplinary, system-wide, 
global response, osteoporosis and the fragility fractures it causes will impose a catastrophic 
burden on our older people, their families and carers, and our health and social care systems. 
However, this is a catastrophe that can be averted.
This review has outlined a stepwise approach to case-finding individuals who are at high risk 
of sustaining fragility fractures. By first closing the secondary fracture prevention care gap, 
up to half of individuals who would otherwise fracture their hip could be treated to prevent 
this debilitating and costly injury. Integration of bone health and falls risk assessments into 
the management of individuals who take medicines which have adverse effects on bone must 
become standard practice. Similarly, individuals who are diagnosed with diseases which 
feature osteoporosis as a common comorbidity need to receive care that will minimise their 
fracture risk. When the needs of these obviously high risk groups have been addressed, we 
must turn our attention to development of cost-effective strategies to prevent the first major 
osteoporotic fracture.
Public awareness of osteoporosis must be increased dramatically throughout the world. 
Effective disease awareness campaigns are needed to ensure that when an older person 
sustains a fragility fracture, their first thought – and that of their family and friends – is ‘Did 
that bone break because of osteoporosis?’  Health professionals and their organisations, 
national patient societies, health system leaders and regulatory agencies must work together 
to craft clear, balanced communications concerning the benefits and risks of treatments, and 
the implications of choosing not to take treatment recommended by a clinician.
Finally, all governments need to establish osteoporosis as a national health priority, with 
commensurate human and financial resources to ensure that best practice is delivered for all 
patients in their jurisdictions. Where the current disease burden is not known, studies to 
close such evidence gaps must be commissioned forthwith.
We cannot ignore the current and growing burden that osteoporosis and fragility fractures 
impose upon our global society. This review clearly illustrates that we have the knowledge 
and tools that we need to manage bone health optimally for all. The time has come to make 
that possibility a reality.
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Mini-abstract
This narrative review considers the key challenges facing healthcare professionals and 
policymakers responsible for providing care to our older people in relation to bone 
health, and proposes globally relevant solutions to those challenges.
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Figure 1. 
A systematic approach to fragility fracture care and prevention for New Zealand [66, 67]
Reproduced with kind permission of Osteoporosis New Zealand
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Figure 2. 
Post-fracture osteoporosis assessment and/or treatment in the United States [138]
n.b. The data presented is for the Healthcare Effectiveness Data and Information Set 
(HEDIS®) measure Osteoporosis Management in Women Who Had a Fracture. This 
represents the percentage of women aged 65 to 85 years who sustained a fracture and who 
had either a BMD test or a prescription for a drug to treat osteoporosis in the six months 
after the fracture.
Reproduced with permission from The State of Health Care Quality Report 2015 by the 
National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of 
the National Committee for Quality Assurance (NCQA). To obtain a copy of this 
publication, contact NCQA Customer Support at +1-888-275-7585 or www.ncqa.org/
publications.
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Table 1
Statistically significant findings (p<0.05) of Cochrane systematic reviews for secondary fracture prevention 
with oral bisphosphonates for postmenopausal women
Treatment Hip fracture reduction (%) Vertebral fracture reduction (%) Non-vertebral fracture reduction 
(%)
Reference
RRRa
(95% CIc)
ARRb RRR (95% CI) ARR RRR (95% CI) ARR
Alendronated 53 (15-74) 1 45 (31-57) 6 23 (8-36) 2 Wells et al [11]
Etidronatee - - 47 (13-68) 5 - - Wells et al [12]
Risedronatef 26 (6-41) 1 39 (24-50) 5 20 (10-28) 2 Wells et al [13]
a
RRR = Relative Risk Reduction
bARR = Absolute Risk Reduction
cCI = Confidence Interval
d10 mg daily dose
e400 mg daily dose
f5 mg daily dose
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Table 2
Fracture Liaison Service models of care of varying intensity and outcomes [33]
FLS Model Proportion investigated with BMD testing Proportion initiated on osteoporosis treatment
Type A: 3i FLS model 79% 46%
Type B: 2i FLS model 60% 41%
Type C: 1i FLS model 43% 23%
Type D: ‘ Zero I’  FLS model - 8%
Reproduced with kind permission of Springer
Osteoporos Int. Author manuscript; available in PMC 2017 November 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Harvey et al. Page 39
Table 3
Vertebral fractures as a proportion of Fracture Liaison Service case loads
Country FLS location Vertebral fractures (%) Reference
Australia Royal Newcastle Hospital 1.6 Giles et al [38]
Canada St. Michael’ s Hospital, Toronto 1.7 Bogoch et al [39]
Netherlands Eindhoven 5.4 Blonk et al [40]
Switzerland University Hospitals of Geneva 5.5 Chevalley et al [41]
UK Cambridge 0.1 Premaor et al [42]
UK Glasgow 2 McLellan et al [43]
UK Ipswich 1.8 Clunie et al [44]
USA University of Wisconsin 6.1 Harrington et al [45]
Reproduced with kind permission of Optasia Medical Ltd
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Table 4
Proportion of women in European countries with and without prior fracture history in 2010
Country Women aged ≥50 
yearsa
Women with prior history of ≥1 
fracturea (%)
Women without prior fracture 
historya (%)
Reference
France 12,200 1,272 (10.4) 10,928 (89.6) Cawston et al [70]
Germany 17,661 2,490 (14.1) 15,171 (85.9) Gauthier et al [71]
Italy 12,900 2,093 (16.2) 10,807 (83.8) Piscitelli et al [72]
Sweden 1,836 0.418 (22.8)b 1,418 (77.2) Gauthier et al [69]
UK 11,494 1,544 (13.4) 9,950 (86.6) Gauthier et al [73]
a
In thousands
bValue for 2010 estimated by creation of linear series based on values for 2009 and 2020 specified in publication
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Table 5
Relative proportions of women and men in European countries with a prior history of hip or vertebral fracture 
in 2010 [74]
Country Women 
aged ≥50 
yearsa
Men aged 
≥50 
yearsa
Prior history of hip fracturea Ratio of % 
women to 
% men
Prior history of vertebral 
fracturea
Ratio of % 
women to 
% men
Women (%) Men (%) Women (%) Men (%)
France 12,358 10,287 328.7 (2.7) 106.0 (1.0) 2.7 310.9 (2.5) 124.6 (1.2) 2.1
Germany 17,764 15,246 489.5 (2.8) 180.3 (1.2) 2.3 555.6 (3.1) 219.9 (1.4) 2.2
Italy 12,997 10,791 384.5 (3.0) 132.6 (1.2) 2.5 387.6 (3.0) 151.4 (1.4) 2.1
Sweden 1,830 1,659 66.6 (3.6) 32.4 (2.0) 1.8 74.4 (4.1) 36.9 (2.2) 1.9
UK 11,534 10,102 293.1 (2.5) 125.8 (1.2) 2.1 292.1 (2.5) 145.4 (1.4) 1.8
a
In thousands
Osteoporos Int. Author manuscript; available in PMC 2017 November 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Harvey et al. Page 42
Table 6
Drug classes associated with bone loss and/or fragility fractures
Drug class Loss of BMD [81] Increased fracture risk [81] Literature review
Androgen deprivation therapy Gonadotropin-releasing hormone 
agonists (GnRHs) are the most 
commonly used ADT. BMD declines 
by 2-5% during the first year of ADT.
The risk of hip and vertebral fractures 
increases to 20-50% after 5 years of 
ADT. Fracture risk correlates with 
age, rate of BMD loss and ADT 
exposure.
Bienz and Saad [82]
Anticoagulants Long-term heparin use leads to loss of 
BMD. Up to 30% of heparin-treated 
pregnant women lose BMD.
2.2-3.6% of heparin-treated pregnant 
women sustain fractures. 15% of non-
pregnant women long-term users 
sustain vertebral fractures.
Coppola et al [83]
Anticonvulsants In epilepsy, ACs are associated with 
bone loss in men >65 years and 
postmenopausal women. Phenytoin has 
been associated with BMD loss in 
young women.
Meta-analysis has shown treatment 
with ACs to be associated with 
increased fracture risk, with a relative 
risk (RR) of 2.2. Fracture risk is 
dependent on duration and dose.
van der Kruijs et al 
[84]
Aromatase inhibitors The annual rate of bone loss in women 
taking AIs is approx. 2.5% as compared 
to 1-2% for healthy postmenopausal 
women [85].
Women treated with AIs have a 30% 
higher fracture risk than age-matched 
healthy women. AI users sustain more 
peripheral fractures than hip or 
vertebral fractures [85].
Rizzoli et al [85]
Calcineurin inhibitors The direct effect of CIs on BMD is not 
clear due to post-transplant GC use and 
compromised bone health before 
transplants.
Several studies suggest that CIs are 
associated with fragility fractures in a 
dose and duration dependent fashion.
Lan et al [86]
Glucocorticoids While all recipients of GCs are at 
increased risk of bone loss, older men 
and postmenopausal women are at 
highest risk with GC doses of >20 mg 
daily.
30-50% of patients receiving GCs 
develop fractures. GC-induced 
osteocyte apoptosis leads to early 
increase in fracture risk prior to loss 
of BMD.
Whittier and Saag [87]
Medroxyprogesterone acetate Depot MPA has been shown to reduce 
BMD by 2-8%. Bone loss is rapid 
during the first 2 years of treatment 
then stabilises.
Depot MPA is associated with a slight 
increase in fracture risk. More studies 
are needed to definitively assess the 
impact on fracture risk.
Lopez et al [88]
Proton pump inhibitors There is no clear association between 
PPI use and loss of BMD. The 
mechanism by which PPIs increase 
fracture risk is unknown.
PPIs use is associated with a modest 
increase in fracture risk. Fracture risk 
appears to be related to duration of 
PPI use.
Lau et al [89]
Selective serotonin reuptake 
inhibitors
Small studies have found an association 
between SSRI use and bone loss. 
However, meta-analysis has reported 
SSRI-related fractures in the absence of 
bone loss.
Two meta-analyses have reported the 
adjusted odds ratio for fracture among 
SSRI users to be approx. 1.7. Fracture 
risk is dependent on dose and duration 
of SSRI treatment.
Rizzoli et al [90]
Thiazolidinediones TZDs reduce bone formation through 
impairing differentiation of osteoblast 
precursors, and increase resorption 
through several mechanisms, resulting 
in bone loss.
Two meta-analyses have reported that 
TZDs significantly increase fracture 
incidence in women with Type 2 
diabetes, but not in men. Notably, 
fracture risk is increased in young 
women without risk factors.
Napoli et al [91]
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Table 7
Examples of diseases associated with bone loss and/or fragility fractures
Disease Global prevalence (millions) Evidence for increased risk of bone loss or 
fractures
Evidence for osteoporosis care gap Disease specific bone 
health guidelines
Diabetes 415 [107] Meta-analyses have shown both Type 1 and Type 2 
diabetics to be at increased risk of hip fracture [113, 
114]. Relative risk (RR) for Type 1 is 6.3-6.9 and RR 
for Type 2 is 1.4-1.7 [114].
There is currently a lack of studies on the 
proportion of diabetics receiving bone health 
assessment.
No
Chronic obstructive 
pulmonary disease (COPD)
65 [108] Systematic literature review established the average 
prevalence of osteoporosis among COPD patients to 
be 35% [115]. The prevalence of vertebral fractures is 
high, ranging from 49-63% dependent on GC use 
[116].
Among a large cohort (n=12,646) of men with 
hip fracture in the US Veteran’ s Health Affairs 
system, nearly half (47.6%) had COPD [121]. 
Osteoporosis was known pre-fracture in only 
3% of subjects.
The Netherlands [126]
Diseases of malabsorption 42 (Celiac) [109]
5 (IBDa) [110]
A UK study evaluated fracture risk in people with 
celiac disease. The overall hazard ratio for any 
fracture was 1.30 (95% CI, 1.16-1.46), for hip 
fracture was 1.90 (95% CI, 1.20-3.02), and for ulna or 
radius fracture was 1.77 (95% CI, 1.35-2.34) [117].
A large cohort (n=6,027) with IBD in Canada had 
40% higher fracture incidence than the general 
population [118].
Studies from Austria [122] and the United 
States [123] have reported that approximately 
one quarter of IBD patients underwent BMD 
testing.
Several national 
guidelines e.g. UK [127]
Dementia 44 [111] In the UK, incidence of hip fracture among patients 
with Alzheimer’ s disease is 3 times higher than 
amongst cognitively healthy peers [119].
Studies from several countries report that 
osteoporosis is infrequently diagnosed and 
treated in people living with dementia e.g. 
Canada. Among a large cohort (n=39,452) 
treated for osteoporosis, a diagnosis of 
dementia was a negative predictor of treatment 
(adjusted Odds Ratio 0.55, 95% CI 0.44-0.69) 
[124].
No
Rheumatoid arthritis (RA) 17 [112] A large UK study (n=30,000) compared fracture 
incidence of RA patients to a control group. The RA 
patients’  risk of hip fracture and vertebral fracture 
was increased 2-fold and 2.4-fold, respectively [120].
Studies from several countries report sub-
optimal assessment and/or treatment of 
osteoporosis in RA patients e.g. USA. Less 
than half of a large cohort (n=9,600) of 
veterans with RA received preventive treatment 
for osteoporosis [125].
Several national 
guidelines and EULAR 
[128]
a
IBD = Inflammatory Bowel Diseases (i.e. Crohn’ s disease and ulcerative colitis)
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Table 8
Fragility fracture prevention in national policy
Region Countries with osteoporosis as a national health priority References
Asia-Pacific Australia, China, Chinese Taipei, New Zealanda, Singapore. 5/16 
countries.
IOF 2013 [101]
Eastern Europe and Central Asia Republic of Belarus, Bulgaria. 2/21 countries. IOF 2010 [144]
European Union Bulgaria, Finland, France, Italy, Luxembourg, Portugal, Romania, 
Sweden, UK. 9/27 member states.
IOF-EFPIA 2013 [74, 75, 
145]
Latin America Brazil, Cuba, Mexico. 3/14 countries. IOF 2012 [147]
Middle East and Africa Iran, Iraq and Jordan. 3/17 countries. IOF 2011 [148]
aSignificant progress has been made in New Zealand since the 2013 IOF Asia-Pacific Audit [67]
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